Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Purpose: To determine the benefit, measured as complete removal of a tumor so that no tumor cells are detectable during histopathologic examination of the resection margin (R0 resection rate), of induction chemotherapy plus chemoradiotherapy (CRT) compared with chemotherapy alone for unresectable pancreatic tumors.

Patients And Methods: CONKO-007, an investigator-initiated open-label, multicentric, phase III randomized clinical trial, enrolled 525 patients with unresectable tumors, and 495 patients received induction chemotherapy (402 with fluorouracil, irinotecan, and oxaliplatin [FOLFIRINOX] and 93 with gemcitabine). Patients without progression after 3 months of induction chemotherapy (n = 336) were randomly assigned for continuation of the same chemotherapy (n = 167) or CRT (n = 169; 50.

[Diagnosis and assessment of the occupational silica dust lung disease (silicosis) - Clinical Practical Guidelines - On behalf of the German Society of Pneumology and Ventilatory Medicine].

The current revision of the guideline incorporates scientific evidence published since 2016, as well as insights gained from its application in clinical and medico-legal practice. It is specifically intended for medical experts involved in the assessment of quartz dust-induced pneumoconiosis as occupational disease No. 4101, as listed in Annex 1 of the German Ordinance on Occupational Diseases (BKV).

An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.

Background: Prognosis in advanced pancreatic ductal adenocarcinoma (aPDAC) is particularly poor, only few patients benefit from treatment, and there are few biomarkers. The PREDICT trial examined whether first-line time-to-treatment failure (TTF1) predicts second-line treatment failure (TTF2) in aPDAC patients but found no association. We hypothesized that the tumor immune microenvironment (TiME) could correlate with the outcome in this trial and assessed whether tissue features were reflected in peripheral blood.

Optimizing Scalp Cooling: (Ultra)Structural Follicular Characteristic and Restorative Advances.

Background: Scalp cooling has emerged as a promising intervention for mitigating chemotherapy-induced alopecia, particularly in patients undergoing anthracycline- and taxane-based regimens typically associated with complete hair loss. Despite a visible hair retention rate of 53%, efficacy varies significantly among individuals, influenced by modifiable factors including general health, hair follicle characteristics, and treatment protocols.

Methods: This study evaluated 81 breast cancer patients treated with Epirubicin/Cyclophosphamide followed by weekly Paclitaxel application.